Transarterial Chemoembolization and Radioembolization

被引：82

作者：

Sangro, Bruno ^{[1
,2
]}

Salem, Riad ^{[3
]}

机构：

[1] Univ Navarra Clin, Liver Unit, Pamplona 31008, Spain

[2] Ctr Invest Biorned Red Enfermedades Hepat & Diges, Pamplona, Spain

[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Dept Vasc & Intervent Radiol, Chicago, IL 60611 USA

来源：

SEMINARS IN LIVER DISEASE | 2014年 / 34卷 / 04期

关键词：

transarterial chemoembolization; drug-eluting bead transarterial chemoembolization; yttrium; selective internal radiation therapy; radioembolization; UNRESECTABLE HEPATOCELLULAR-CARCINOMA; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; DRUG-ELUTING BEADS; PORTAL-VEIN; Y-90; MICROSPHERES; PREDISPOSING FACTORS; RESIN MICROSPHERES; SURVIVAL ANALYSIS; 5-YEAR SURVIVAL; TUMOR RESPONSE;

D O I：

10.1055/s-0034-1394142

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Transarterial chemoembolization (TACE) and radioembolization (RE) are frequently used to treat patients with hepatocellular carcinoma who cannot receive curative therapies. Transarterial chemoembolization is a heterogeneous group of procedures; based on two positive clinical trials and three meta-analyses, conventional TACE is the standard of care for patients in the intermediate stage. Transarterial chemoembolization with drug-eluting beads has been recently introduced as a more standardized way of performing TACE with similar outcomes and less systemic effects. Radioembolization is a form of brachytherapy in which microspheres are used as a source of internal radiation. Evidence supporting the use of RE derives from consistent, large-cohort series involving patients with more advanced hepatocellular carcinoma, not suitable for TACE or for those who have failed TACE. Transarterial chemoembolization and RE should not be considered competing therapies, but rather complementary tools. The clinical indications for TACE and RE will be further refined as results of ongoing large-scale studies become available.

引用

页码：435 / 443

页数：9